Analysis of the Ex Vivo and In Vivo Antiretroviral Activity of Gemcitabine
2011

Gemcitabine's Antiretroviral Activity Against Murine Leukemia Virus

Sample size: 28 publication 10 minutes Evidence: moderate

Author Information

Author(s): Christine L. Clouser, Colleen M. Holtz, Mary Mullett, Duane L. Crankshaw, Jacquie E. Briggs, Jay Chauhan, Ilze Matise VanHoutan, Steven E. Patterson, Louis M. Mansky

Primary Institution: University of Minnesota

Hypothesis

Gemcitabine would be an alternative to hydroxyurea that could be translated to clinical use for the treatment of retroviral infections when used in combination with current anti-retroviral therapies.

Conclusion

Gemcitabine has potent antiretroviral activity in vivo and ex vivo using the LP-BM5 MuLV model.

Supporting Evidence

  • Gemcitabine decreased MuLV infectivity in cell culture with an EC50 in the low nanomolar range.
  • Treatment with gemcitabine decreased spleen size and plasma IgM levels in infected mice.
  • Gemcitabine was effective at doses as low as 1 mg/kg/day without detectable toxicity.

Takeaway

Gemcitabine is a medicine that can help fight certain viruses without making you sick, and it works better than some older medicines.

Methodology

The study examined gemcitabine's effects on MuLV in cell culture and in C57Bl/6 mice infected with LP-BM5 MuLV.

Potential Biases

Potential bias in the selection of treatment doses and the small number of animals in each treatment group.

Limitations

The study was limited by the small sample size and variability in responses to gemcitabine among mice.

Participant Demographics

C57Bl/6 mice, aged 8-10 weeks.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1371/journal.pone.0015840

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication